Corcept Therapeutics CORT Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's other accrued liabilities?
- Corcept Therapeutics (CORT) reported other accrued liabilities of $12.14M in Q1 2026.
- How has Corcept Therapeutics's other accrued liabilities changed year-over-year?
- Corcept Therapeutics's other accrued liabilities increased by 201.5% year-over-year, from $4.03M to $12.14M.
- What is the long-term trend for Corcept Therapeutics's other accrued liabilities?
- Over 5 years (2020 to 2025), Corcept Therapeutics's other accrued liabilities has grown at a 102.7% compound annual growth rate (CAGR), from $202K to $6.91M.